There is an urgent need for new therapeutics that effectively target drug-resistant microbes and pathogens that currently have no treatment options. Noroviruses cause an estimated 23 million infections and over half of all food-borne gastroenteritis outbreaks in the US every year but no antivirals or vaccines exist to treat or prevent infections. Listeria monocytogenes is another food-borne pathogen with a high fatality rate of 20- 25%, responsible for the recent cantaloupe-associated outbreak. Rapid diagnosis of a specific pathogen during outbreaks is often challenging. Thus, there is a compelling rationale for the development of broad-spectrum therapeutics for early and effective treatment of infectious diseases. One approach towards that goal is to develop anti- infective compounds that target host-encoded proteins critical during infection of multiple microbes. We find that a small molecule, WP1130 (WP) and related compounds, exhibit anti-infective activity against multiple classes of pathogens, including several category B pathogens: bacteria (MRSA, Listeria monocytogenes, Salmonella enterica serovar Typhimurium), viruses (murine and human norovirus, encephalomyocarditis virus, Sindbis virus, La Crosse virus), and an apicomplexan parasite (Toxoplasma gondii). Our initial studies demonstrate that WP inhibits a subset of host deubiquitinases (DUBs) resulting in the accumulation of ubiquitinated proteins in cells, but does not directly affect pathogens outside the host. Ubiquitin is a eukaryotic low molecular weight polypeptide that acts as a post-translational regulatory switch when covalently linked to target proteins. Studies of WP analogs hold vital clues for the development of novel therapeutics that may effectively contain pathogens by interfering with key interactions between host and microbe. Ubiquitination and deubiquination of host targets play critical roles in many different microbial infections. We therefore hypothesize that WP treatment selectively inhibits key DUBs exploited by microbial pathogens, thereby limiting infection. We will use murine norovirus and L. monocytogenes as two unrelated pathogens with established small animal models of infection to define DUB targets that mediate the anti-infective effects of WP. Our goal is to advance the lead compound towards an investigational new drug (IND) application. We therefore propose the following specific aims: (1) Determine target DUBs of WP that mediate anti-infective activity, (2) Test a SAR series of WP in vitro to identify lead compounds, and (3) Test lead compounds for in vivo efficacy. This application aims to develop a broad-spectrum anti-infective therapeutic effective against many pathogens including multiple category B agents.
Infectious agents are a major cause of morbidity and mortality in the United States today, and the emergence of drug resistant organisms is a major public health concern. We have identified a novel compound with anti-infective activity against many microbial pathogens, including drug-resistant bacteria, viruses and parasites. Studies of this compound may hold vital clues for the development of therapeutics that effectively contain pathogens by targeting cellular enzymes critical for effective replication of pathogens.
|Baldridge, Megan T; Turula, Holly; Wobus, Christiane E (2016) Norovirus Regulation by Host and Microbe. Trends Mol Med 22:1047-1059|
|Passalacqua, Karla D; Charbonneau, Marie-Eve; Donato, Nicholas J et al. (2016) Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens. Antimicrob Agents Chemother 60:4183-96|
|Karst, Stephanie M; Wobus, Christiane E (2015) A working model of how noroviruses infect the intestine. PLoS Pathog 11:e1004626|
|Karst, Stephanie M; Wobus, Christiane E (2015) Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses. Annu Rev Virol 2:525-48|
|Hwang, Seungmin; Alhatlani, Bader; Arias, Armando et al. (2014) Murine norovirus: propagation, quantification, and genetic manipulation. Curr Protoc Microbiol 33:15K.2.1-61|